<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546503</url>
  </required_header>
  <id_info>
    <org_study_id>8822</org_study_id>
    <secondary_id>2010-A00443-36</secondary_id>
    <nct_id>NCT04546503</nct_id>
  </id_info>
  <brief_title>Impact of Continuous Regional Analgesia in Severe Trauma Patients</brief_title>
  <acronym>ALRréa</acronym>
  <official_title>Evaluation of the Interest of Regional Locoregional Anesthesia by Perfusion Blocks in Continuous Infusion in Polytrauma Patients With Limb Fractures and Mechanical Ventilation. A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional analgesia, based on its physiological effects and efficacy, is used for optimal&#xD;
      perioperative pain relief. However, for acute pain in multiple trauma patients in a critical&#xD;
      condition, it has not been prospectively studied. The use of regional anaesthesia in this&#xD;
      group of patients extend to the management of trauma patients and of other painful procedures&#xD;
      performed at the patient's bed. The use of RA in such patients must be analyzed in the light&#xD;
      of associated conditions that can increase the risk of systemic toxicity and complications:&#xD;
      coagulopathies, infection, immunosuppressive states, sedation and problems associated with&#xD;
      mechanical ventilation. The investigators aim to assess the role of continuous peripheral&#xD;
      nerve blocks (CPNB) in multiple trauma patients, in order to show the benefits in terms of&#xD;
      opiates consumption decrease, sedation limitation, improvement in ventilator free days and&#xD;
      patients outcome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion of multiple trauma patients with limb fractures and need for sedation and prolonged&#xD;
      mechanical ventilation.&#xD;
&#xD;
      Patients should meet the following criterias: pressure of cerebral perfusion&gt;60mmHg,&#xD;
      normothermia, PaCO2 35-40 mmHg, pH&gt; 7.20, Normal coagulation parameters, Hb&gt; 8g / dl (without&#xD;
      head trauma) or Hb&gt; 10g / dl (if associated head trauma).&#xD;
&#xD;
      Randomization in two patients groups: &quot;RA group&quot; versus &quot;NoRA Group&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      group without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily&#xD;
      adjustment of doses every 4 hours using Behavioral Pain Scale score &lt;4 and Ramsay Score &gt; 4.&#xD;
&#xD;
      group with locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily&#xD;
      adjustment of doses every 4 hours using Behavioral Pain Scale score &lt;4 and Ramsay Score &gt; 4 +&#xD;
      peronerval block catheter from 0 to 24h after admission in intensive care unit using&#xD;
      ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H Follow-up up to 5 days for the 2&#xD;
      group. The main objective: sufentanil consumption (reported in µg / kg / d) for the same&#xD;
      levels of Behavioral Pain Scale and Ramsay Scales values.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">July 31, 2014</completion_date>
  <primary_completion_date type="Actual">July 31, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.&#xD;
Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H&#xD;
group with locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score &lt;4 and Ramsay Score &gt; 4 + peronerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigator responsible for assessing sedation and adjusting dosages hypnotic and morphinic (according to objectives) will not be aware of the result of the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>sufentanil consumption in ICU patients for sedation</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>assess the interest of regional anesthesia in trauma patients with fractures members. sufentanil consumption in ICU patients for sedation (µg/kg/j)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>daily consumption of sufentanil</measure>
    <time_frame>at 24 Hours</time_frame>
    <description>daily consumption of sufentanil (mcg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of sufentanil</measure>
    <time_frame>48 Hours</time_frame>
    <description>daily consumption of sufentanil (mcg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of sufentanil</measure>
    <time_frame>at 72 Hours</time_frame>
    <description>daily consumption of sufentanil (mcg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of sufentanil</measure>
    <time_frame>at 96 Hours</time_frame>
    <description>daily consumption of sufentanil (mcg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of sufentanil</measure>
    <time_frame>at 120 Hours</time_frame>
    <description>daily consumption of sufentanil (mcg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of midazolam</measure>
    <time_frame>at 24 Hours</time_frame>
    <description>daily consumption of midazolam (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of midazolam</measure>
    <time_frame>at 48 Hours</time_frame>
    <description>daily consumption of midazolam (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of midazolam</measure>
    <time_frame>at 72 Hours</time_frame>
    <description>daily consumption of midazolam (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of midazolam</measure>
    <time_frame>at 96 Hours</time_frame>
    <description>daily consumption of midazolam (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of midazolam</measure>
    <time_frame>at 120 Hours</time_frame>
    <description>daily consumption of midazolam (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of noradreline</measure>
    <time_frame>at 24 Hours</time_frame>
    <description>daily consumption of noradreline (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of noradreline</measure>
    <time_frame>at 48 Hours</time_frame>
    <description>daily consumption of noradreline (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of noradreline</measure>
    <time_frame>at 72 Hours</time_frame>
    <description>daily consumption of noradreline (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of noradreline</measure>
    <time_frame>at 96 Hours</time_frame>
    <description>daily consumption of noradreline (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>daily consumption of noradreline</measure>
    <time_frame>at 120 Hours</time_frame>
    <description>daily consumption of noradreline (mg/kg/j)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation duration</measure>
    <time_frame>discharge, up to end of hospitalization (Follow-up up to 5 days)</time_frame>
    <description>number of days between inclusion and the end of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator free days</measure>
    <time_frame>discharge, up to end of hospitalization (Follow-up up to 5 days)</time_frame>
    <description>number of days between inclusion and the end of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of mechanical ventilation</measure>
    <time_frame>discharge, up to end of hospitalization (Follow-up up to 5 days)</time_frame>
    <description>number of days between inclusion and the end of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation complication</measure>
    <time_frame>From the third to the tenth day after inclusion</time_frame>
    <description>the rate of occurrence of pneumopathy acquired under mechanical ventilation (between 3rd and 10th day of developmen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Limb Fracture</condition>
  <arm_group>
    <arm_group_label>Continuous Regional Analgesia group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score &lt;4 and Ramsay Score &gt; 4 + perinerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group with general anesthesia and without locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score &lt;4 and Ramsay Score &gt; 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Regional analgesia</intervention_name>
    <description>Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.&#xD;
Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H&#xD;
+ General anaesthesia</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>General anaesthesia without regional analgesia</description>
    <arm_group_label>Continuous Regional Analgesia group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient older than 18 years&#xD;
&#xD;
          -  Multiple trauma Patient ( with or without head trauma)&#xD;
&#xD;
          -  Patient admitted to ICU&#xD;
&#xD;
          -  Patient with limb fracture (s)&#xD;
&#xD;
          -  Patient requiring sedation and mechanical ventilation for more than 48h&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Patient whose informed consent was obtained from the family&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient currently enrolled in another trial&#xD;
&#xD;
          -  Patient with coagulation disorders&#xD;
&#xD;
          -  Patient whose access to the puncture sites is not feasible (underlying lesions)&#xD;
&#xD;
          -  Patient with allergies to local anesthetics (LA)&#xD;
&#xD;
          -  Patient whose family did not give informed consent&#xD;
&#xD;
          -  Patient younger than 15 years and 3 months&#xD;
&#xD;
          -  Tetraplegic Patient&#xD;
&#xD;
          -  Dying patients&#xD;
&#xD;
          -  Patients with more than 3 different fracture sites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>183 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oriane MARTINEZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia Resuscitation at the Hospital Lapeyronie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensive Care Unit ; limb fracture ; regional analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

